Hologic (NASDAQ:HOLX) CEO Stephen Macmillan purchased 38,600 shares of the stock on the open market in a transaction dated Tuesday, February 11th. The stock was purchased at an average price of $21.58 per share, with a total value of $832,988.00. Following the acquisition, the chief executive officer now directly owns 237,500 shares of the company’s stock, valued at approximately $5,125,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
HOLX has been the subject of a number of recent research reports. Analysts at Cantor Fitzgerald reiterated a “buy” rating on shares of Hologic in a research note on Tuesday, February 4th. They now have a $21.00 price target on the stock. Separately, analysts at ISI Group reiterated a “buy” rating on shares of Hologic in a research note on Tuesday, February 4th. They now have a $24.50 price target on the stock. Finally, analysts at ISI Group downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 22nd. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have given a buy rating to the company. Hologic has an average rating of “Hold” and a consensus target price of $21.97.
Shares of Hologic (NASDAQ:HOLX) opened at 21.41 on Thursday. Hologic has a 52-week low of $18.46 and a 52-week high of $23.24. The stock has a 50-day moving average of $21.65 and a 200-day moving average of $21.82. The company’s market cap is $5.839 billion.
Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, February 3rd. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.03. The company had revenue of $612.40 million for the quarter, compared to the consensus estimate of $609.65 million. During the same quarter in the previous year, the company posted $0.38 earnings per share. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Analysts expect that Hologic will post $1.37 EPS for the current fiscal year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.